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COMPARISON OF DIFFERENT EXHALATION FILTERS IN PROTECTION AGAINST 
FUGITIVE AEROSOL DURING NEBULIZER TREATMENTS: AN IN-VITRO STUDY  
By 
Li-Sheng Chen 
(Under the Direction of Dr. Douglas S. Gardenhire) 
ABSTRACT 
Background: Aerosol escaping to the environment during nebulization treatments is called 
fugitive aerosol. Placing a filter at the exhalation outlet is one way to prevent unintended 
inhalation of fugitive aerosol by healthcare providers. Aim: To determine the best exhalation 
filter in preventing fugitive aerosol from escaping to the environment.  
Methods: Three brands of exhalation filters were tested in our study, the Westmed filter, 
Airlife filter, and Microgard filter. They were attached at the exhalation outlet of the Circulaire 
II nebulizer with a collection filter sitting right after. Each filter was nebulized for three 
consecutive tests before being discarded. For each test, albuterol (2.5 mg/0.5 ml equivalent to 
3 mg of albuterol sulfate) was nebulized to a simulated breathing adult patient (VT 500 ml, RR 
15 BPM) by a flowmeter powered with 8 LPM for five minutes. After completion of each test, 
the collection filter was rinsed and gently stirred with 0.1N of HCl before being analyzed by a 
spectrophotometry device for the determination of fugitive dose.  
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Results: All types of exhalation filters allowed less than 0.4% of the nominal dose to escaped 
for each nebulization test. There were no differences in fugitive dose between each exhalation 
filter within the three nebulization tests (p >0.05), and the average of the three tests (p >0.05). 
There was also no difference in fugitive dose between each test for the same type of exhalation 
filter (p >0.05).  
Conclusion: Regardless of the exhalation filter tested, all offer similar protection against 
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CHAPTER I  
INTRODUCTION 
 Respiratory therapists (RTs) are the most crucial healthcare workers for treating patients 
with respiratory-related diseases. They’re trained to perform various therapies to aid patients 
in recovery, and delivering aerosolized treatments through nebulizers is the most common of 
all. While aerosolizing medications alleviate the burden of diseases for patients, healthcare 
workers like RTs on the other hand might potentially be harmed by unexpected exposure to 
them. This has always been a concern in nebulizer treatments, and methods to reduce the 
exposure to healthcare workers are always of interest.  
THE STATEMENT OF THE QUESTION 
 There have been several proposed routes to reduce accidental inhalation of aerosolized 
drugs in different scenarios(Ari et al., 2016; James A. McGrath, O’Sullivan, et al., 2019; Tsai 
et al., 2015; Bart P.H. Wittgen et al., 2006), one of which is to insert a filter at the expiration 
port connected to a nebulizer and patient interface in simulated spontaneously breathing 
patients(James A. McGrath, O’Sullivan, et al., 2019). While this method looks promising, our 
next question is, what kind of exhalation filter protects healthcare workers best? Thus, the 
purpose of this study is to compare different brands of exhalation filters in preventing 
aerosolized drugs from contaminating the environment. 




 The discussion on the occupational hazard of providing aerosol treatments has been 
extensively studied(Ari et al., 2016; Croteau et al., 2004; Elmashae et al., 2019; Ishau et al., 
2020; James A. McGrath, O’Sullivan, et al., 2019; James A. McGrath, O’Toole, et al., 2019; 
O’Riordan & Smaldone, 1992; Saeed et al., 2017; Tsai et al., 2015; Bart P.H. Wittgen et al., 
2006). Aerosol escaping to the environment either from the nebulizer or the patient is called 
fugitive aerosol. It is imperative to protect healthcare workers from inhaling fugitive aerosol 
containing drugs that could cause undesired side effects and the risk of developing 
asthma(Christiani & Kern, 1993). Especially in times like this with the pandemic of 
coronavirus disease 2019 (COVID19), people now seek maximum protection from hazardous 
aerosol more than ever. Healthcare workers not only have to worry about being exposed to 
aerosolized drugs, but they also have to worry about fugitive aerosol contaminated with 
COVID19 from the patient. There are proposed guidelines on how to safely deliver aerosol 
treatments to COVID19 patients, and they recommended attaching the exhalation filter to 
prevent contamination of the environment(Ari, 2020; Benge & Barwise, 2020). The effort of 
those guidelines along with previous studies is to provide healthcare workers more information 
about the risk of fugitive aerosol and how to prevent them, hence, knowing which type of 
exhalation filter that provides the most protection will prove beneficial.  




 We hypothesize that different brands of exhalation filters will have varying protection 
against fugitive aerosol during nebulizer treatments in spontaneously breathing patients. The 
purpose of this in-vitro study is to compare different brands of exhalation filters in protecting 
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CHAPTER II  
BACKGROUND 
 Aerosol treatments have been used to deliver extensive varieties of drugs to patients with 
pulmonary conditions. From simple bland aerosol treatment to aerosolized bronchodilators and 
antibiotics, they are all meant to alleviate burdens of pulmonary diseases from the patient. The 
benefits of delivering aerosolized drugs to patients are faster onset on targeted organs and lower 
systemic effects. Respiratory therapists (RTs) are experts in utilizing different kinds of 
nebulizers that would deliver particle size mainly between 1 to 8 μm and resolve a variety of 
respiratory-related issues(Wang et al., 2017).  
 While most studies are interested in drug deposition to the patient during aerosol 
treatments, few have examined that did not. Aerosol generated by a nebulizer that escaped from 
the nebulizing system or failed to deposit in the respiratory tract and exhaled to the environment 
is called the fugitive aerosol. When unintentionally inhaled by bystanders such as RTs, it might 
cause deleterious side effects and increase the risk of developing occupational asthma 
accompany by familial economic crisis(Barnes et al., 1996; Blanc et al., 1999, 2003; Weiss et 
al., 1992). Many factors dictate the amount of fugitive aerosol contaminating the environment 
and threatening the health of bystanders during nebulizer treatments. Context-related key 
factors include interzonal airflow rate, external airflow rate, air-exchange rate, deposition rate, 
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particle resuspension, and particle coagulation(He et al., 2005; J.A. McGrath et al., 2014a, 
2014b; W. W. Nazaroff, 2004; William W Nazaroff, 2016). Nebulizer and patient-related key 
factors include nebulizer types, nebulizing durations, supplemental gas flow rate, patient 
interface, distance from the nebulizing source, and fill volume inside nebulizer(Elmashae et 
al., 2019; James A. McGrath, O’Sullivan, et al., 2019; James A. McGrath, O’Toole, et al., 
2019; Rau et al., 2004; Saeed et al., 2017). 
The topic of fugitive aerosol harming healthcare workers has always been concerning 
either in hospital or home care settings. Aerosolized drugs such as Pentamidine, ribavirin, 
Adeno-associated virus serotype 2 vector containing cystic fibrosis transmembrane 
conductance regulator complementary DNA, sustained-release lipid inhalation targeting 
cisplatin, and glutaraldehyde have all been highlighted as they are associated with occupational 
hazards when healthcare workers are exposed to their fugitive aerosol(Croteau et al., 2004; 
Dimich-Ward et al., 2004; McDiarmid et al., 1992, 1993; O’Riordan & Smaldone, 1992; Tsai 
et al., 2015; B. P.H. Wittgen et al., 2007). In addition to harmful drugs escaping to the 
environment with fugitive aerosol, infectious pathogens like influenza, 
mycobacterium tuberculosis, and severe acute respiratory syndrome coronavirus could also be 
transmitted through escaping aerosol during common oxygen therapies(Simonds et al., 2010; 
Tran et al., 2012). Patients in severe respiratory failure requiring invasive mechanical 
ventilation have compromised upper airway due to the insertion of an endotracheal tube. They 
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are more susceptible to lower respiratory tract infection and have the potential to spread 
pathogens like gram-positive bacterias, gram-negative bacterias, viruses or fungi from their 
lungs to the ventilator circuit, then to the environment (da Silveira et al., 2019; Jaiswal et al., 
2018; Kelly et al., 2016; Mitchell et al., 2018; Nazareth et al., 2020; Picazo et al., 2020; 
Sommerstein et al., 2019; Tsakiridou et al., 2018, p.; Zakharkina et al., 2017). 
Recently, a global outbreak of coronavirus disease 2019 (COVID19) has struck the world 
off guard. The pathogen is transmitted through droplet and airborne(Y. Liu et al., 2020), which 
means patients with COVID19 needing aerosol treatments could contaminate the environment 
with COVID19 pathogen, carried by fugitive aerosol increasing the risk of healthcare workers 
being infected when rendering care. To make matter worse, shortage of N95 masks has taken 
a toll on healthcare providers worldwide, thus, some have proposed attaching filters onto 
commercially available elastomeric respirators to substitute N95 masks(D. C. Y. Liu et al., 
2020). There are also guidelines proposed on how to safely deliver nebulizer treatments to 
COVID19 patients, and putting an exhalation filter at the expiratory port is one of the 
options(Ari, 2020; Benge & Barwise, 2020; Fink et al., 2020; Respiratory Care Committee of 
Chinese Thoracic Society, 2020). All the efforts mentioned above are to protect healthcare 
workers from inhaling fugitive aerosols containing COVID19 when providing therapies like 
aerosol treatment. This concept is similar to other studies showing less fugitive aerosol 
spreading to the environment when a filter is placed at the exhalation limb of a ventilator circuit 
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(Ari et al., 2016; O’Toole et al., 2020) or the exhalation port of a breathing system intended for 
nebulizer treatments (Mac Giolla Eain et al., 2021; James A. McGrath, O’Sullivan, et al., 
2019), it minimizes secondary exposure to unintended personnel. 
The idea of having an exhalation filter sit at the expiratory port to prevent fugitive aerosol 
sounds promising. To the best of our knowledge, limited data have compared different kinds 
of exhalation filter in their ability to minimize secondary exposure during nebulizer treatments, 
thus, the purpose of this article is to compare different exhalation filters in their efficiency to 
stop fugitive aerosol from contaminating the environment with commonly seen nebulizers in 
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CHAPTER III  
RESEARCH DESIGN 
 This is an original article conducted in the form of a bench study. The main objective was 
to describe different brands of exhalation filters in their efficiency to prevent fugitive aerosol 
from escaping to the environment during aerosol treatments. No human subject was involved 
in the study, thus, no institutional review board approval was needed prior. 
NEBULIZERS AND DRUG 
 Circulaire II available on the market of the United States (Westmed, Tucson, AZ, USA) 
was utilized in the study (Figure 1). Albuterol (2.5mg/3 ml, equivalent to 3mg of albuterol 
sulfate) (Nephron Pharmaceuticals Corporation, West Columbia, SC, USA), a common 
bronchodilator in clinical was the drug of choice to be nebulized. 
EXHALATION FILTERS 
 We tested 3 different exhalation filters in this study (Figure 1). The Westmed filter 
(Westmed, Tucson, AZ, USA) that comes with the Circulaire II package, the AirLife filter 
(CareFusion, Yorba Linda, CA, USA), and the MicroGard filter (CareFusion Germany, 
Hoechberg, Bavaria, Germany). Exhalation filters from different brands were attached 
appropriately to the exhalation outlet of Circulaire II, followed by a collecting filter 
(CareFusion, Yorba Linda, CA, USA) placed directly after the tested exhalation filter. 
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Aerosolized albuterol caught in the collecting filter represented fugitive aerosol that bypassed 
the exhalation filter and into the environment. The peep valve of Circulaire II was not used in 
our study. 
Figure 1 
Exhalation filters and nebulizer tested 
 
The three exhalation filters and nebulizer tested are shown above. A: Westmed filter; B: Airlife 
filter; C: Microgard filter; D: Circulaire II 
SIMULATED PATIENT MODEL 
 This study utilized an ASL5000 breathing simulator (IngMar Medical, Pittsburgh, PA, 
USA) to mimic healthy spontaneously breathing adult patients. The Circulaire II/exhalation 
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filter complex was connected to the ASL5000 with two protection filters (CareFusion, Yorba 
Linda, CA, USA) in between. The settings for the ASL5000 breathing simulator were 
respiratory rate 15 breaths per minute, tidal volume 500 ml, lung compliance 0.05 L/cmH20, 
and airway resistance 6 cmH20/L/sec.  
VARIABLES 
 There was one independent variable in this study, the different brands of exhalation filter. 
There was one dependent variable, the fugitive dose, expressed as the percentage of the 
nominal dose administered to the nebulizer. 
SETTINGS 
 The study was carried out in the Aerosol Research Laboratory located in the Department 
of Respiratory Therapy at Georgia State University, United States of America. 
EXPERIMENT PROTOCOL 
 We utilized 3 identical but separate Circulaire II and exhalation filters of each type. Each 
exhalation filter was tested 3 times repeatability on each Circulaire II before being discarded, 
which resulted in 27 nebulization trials overall. For each trial, after proper Circulaire 
II/exhalation filter complex setup (Figure 2), albuterol sulfate solution was administered into 
the jet nebulizer of Circulaire II. The jet nebulizer was powered with 8 L/min of 100% oxygen 
flow from a flowmeter while simultaneously activating ASL5000 for 5 minutes. After 5 
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minutes, the collecting filter with albuterol sulfate deposited was rinsed with 10 ml of 0.1 N 
hydrochloric acid (JT Baker Company, Phillipsburg, NJ, USA). To ensure proper and balanced 
mixing, the solution was gently stirred for 3 minutes, then collected into a cuvette. A calibrated 
spectrophotometry device (Beckman Instruments, Fullerton, CA, USA) ultimately measured 
albuterol sulfate concentration in the cuvette using the wavelength of 273 nm. By utilizing the 
equation 0.173*absorbance*10/3, it will give us the amount of albuterol sulfate captured (in 
mg). Since each Circulaire II/exhalation filter experiment was repeated 3 times, and conducted 
on 3 separate Circulaire, it gave us 3 independent experiments (n=3). 
Figure 2 
Illustration of Circulaire II/exhalation filter setup 
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Experimental outline for this study 
 
A diagram showing the outline of experiments in the study  
STATISTICAL ANALYSIS 
 The Statistical Package For The Social Sciences (SPSS) 27th version (IBM Corp., 
Armonk, NY, USA, 2020) was used for the analysis of the study. Utilizing descriptive analysis, 
the fugitive dose was expressed as the percentage±SE of the nominal dose administered to the 
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nebulizer. One-way analysis of variance (ANOVA) was used to compare differences in fugitive 
dose among different brands of exhalation filter, while repeated-measures ANOVA was used 
for the comparison of the same exhalation filter. The Bonferroni correction was used for the 
post-hoc test. A p-value of less than 0.05 was considered to be statistically significant. 
DATA MANAGEMENT AND STORAGE 
 Study data collected were all stored in a computer database (SPSS). A codebook was 
created before data entry to ensure accurate and reliable study results. The computer used for 
data storage had restricted access strictly to researchers related to the study by passwords. The 
Data Management Advisory Team (DMAT) of Georgia State University was available during 
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CHAPTER IV  
RESULTS 
 Table 1 shows the fugitive dose (mean±SE in percent of nominal dose) for each exhalation 
filter in each test and the average of 3 tests. Raw data for our study could be found in 
Supplemental Table 1 in appendices. 
COMPARISON OF FUGITIVE DOSE IN EACH TEST BETWEEN EXHALATION 
FILTERS 
 To determine if there’s a difference in filter protection efficiency after exposure to 
multiple nebulization tests (3 for this study), one-way ANOVA was utilized to compare the 
fugitive dose of each test between different brands of exhalation filter. The findings of this 
study showed no difference in the protection efficiency between exhalation filters during each 
nebulization test [F(2, 6) = 0.362, p=0.710, for 1st test] [F(2, 6) = 1.041, p=0.409, for 2nd test] 
[F(2, 6) = 4.436, p=0.066, for 3rd test]. 
COMPARISON OF MEAN FUGITIVE DOSE BETWEEN EXHALATION FILTERS 
 To contrast the overall protection efficiency of each exhalation filter, we calculated the 
mean fugitive dose for the 3 tests of each exhalation filter and utilized one-way ANOVA for 
comparison. Our results showed no difference in the overall protection efficiency between 
exhalation filters [F(2, 6) = 1.717, p=0.257]. 
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COMPARISON OF FUGITIVE DOSE BETWEEN EACH TEST FOR THE SAME 
FILTER TYPE 
 Clinically, the same nebulizer/exhalation filter complex would be used several times 
before being discarded. To determine if the filter protection efficiency would differ after each 
nebulization test (up to 3 in this study), we utilized repeated-measure ANOVA. Our findings 
showed no difference in filter protection efficiency between each test for the same filter type 
[F(1, 2) = 3.441, p= 0.205, for Westmed filter] [F(2, 4) = 1.998, p= 0.250, for Airlife filter] 
[F(2, 4) = 1.176, p= 0.397, for Microgard filter].   
Table 1 
Fugitive dose expressed in percent of nominal dose (mean±SE) for each type of exhalation 
filter. The mean fugitive dose for 3 repeated tests of each filter is also calculated. 
Circulaire II 
     Measurement 
Filter type      
Fugitive dose on 
1st test 
Fugitive dose on 
2nd test 




Westmed filter 0.19±0.1% 0.31±0.1% 0.34±0.1% 0.28±0.1% 
Airlife filter  
 
0.14±0.0% 0.24±0.1% 0.28±0.1% 0.22±0.1% 
Microgard filter  
 
0.17±0.0% 0.15±0.0% 0.14±0.0% 0.15±0.0% 
 
 




Fugitive aerosol among three exhalation filters during each test run  
 
Fugitive aerosol escaping to the environment among the three exhalation filters for each test 
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CHAPTER V  
DISCUSSION 
 Patients have the right to receive proper treatments to ease the burden of diseases, while 
healthcare providers have the right to be free of harm during the process of delivering care, and 
that includes aerosol treatments. The idea of providing therapeutic aerosol to patients in need 
is justifiable, but how we protect bystanders such as RTs from fugitive aerosol remains a true 
question. We know placing an exhalation filter during nebulizer treatment would protect the 
surrounding environment from fugitive aerosol (Ari et al., 2016; Mac Giolla Eain et al., 2021; 
O’Toole et al., 2020), but different brands of exhalation filters would have varying protection 
efficiency, thus, this study intends to find the best exhalation filter regarding protection 
efficiency. According to our results, an average of less than 0.4% of albuterol nominal dose 
escaped to the environment for all types of tested exhalation filters during the first three 
nebulization trials. We demonstrated trends of increasing fugitive dose after each nebulization 
test for Westmed and Airlife filter, while Microgard presented the opposite, though all were 
not statistically significant (Table 1). After averaging the fugitive dose from three nebulization 
tests, the Westmed filter allowed almost twice the amount of fugitive aerosol to escaped 
comparing to the Microgard filter, again, it wasn’t statistically significant (Table 1). To the best 
of our knowledge, no study that investigates the protection efficiency from aerosolized drugs 
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between different exhalation filters has been published so far, thus, we can not compare our 
results with other similar studies.  
 While most studies focus on the amount of aerosolized drug delivered to the patient, few 
have looked into the fugitive aerosol hazard. Interestingly, one study found around 30% of 
albuterol nominal doses escaped to the environment during jet nebulization therapy for 
spontaneously breathing patients without an exhalation filter in place (James A. McGrath, 
O’Sullivan, et al., 2019). Another study that utilized Circulaire II to nebulized albuterol also 
found around 12% of the nominal dose escaping to the environment without an exhalation filter 
at the exhalation outlet (Rau et al., 2004). Their results underline the importance of exhalation 
filters, which in our study, only less than 0.4% of nominal dose were allowed to escape with 
exhalation filter inserted, regardless of the type of exhalation filter.  
 According to different sources, the occupational exposure limit for albuterol stands 
between 2 mcg/day (Frank et al., 2019) to 10 mcg/8 hr (Nephron Pharmaceuticals, 2021). The 
observed fugitive aerosol for our study stands between 2.48 mcg to 14.5 mcg for each 
nebulization test, with an average of 4.6 mcg to 8.4 mcg overall throughout the 3 tested 
exhalation filters (Supplemental Table 1). These fugitive dosages are obtained right at the 
exhalation outlet of the Circulaire II, and there is a list of factors that would dictate the amount 
of accidental inhalation by healthcare workers nearby, such as context-related, nebulizer-
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related, and patient-related key factors, as stated earlier (Elmashae et al., 2019; He et al., 2005; 
J.A. McGrath et al., 2014a; James A. McGrath, O’Toole, et al., 2019; W. W. Nazaroff, 2004; 
William W Nazaroff, 2016; Rau et al., 2004; Saeed et al., 2017). Since there were no 
differences in protection efficiency of the three tested exhalation filters for the first 3 
nebulization run, the safest method to minimize occupational exposure to aerosolized drugs is 
simply ensuring the placement of an exhalation filter for every patient, regardless of type, and 
changing them every day for optimal protection efficiency as most patients would only need 
an average of 3 to 4 nebulization treatments per day. 
CLINICAL IMPLICATIONS 
 It is crucial to protect healthcare workers from inhaling excessive fugitive aerosol 
generated by nebulizer treatments, which is why it is vital to find the best exhalation filter that 
provides the most protection. This study demonstrated similar protection efficiency among the 
three tested exhalation filters during the first three nebulizer treatments for spontaneously 
breathing patients. Therefore, with the evidence provided by our study, it is safe to utilize any 
of the three tested exhalation filters without having to worry about inferior protection ability, 
given the filter is changed every day. 
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SUGGESTIONS FOR FUTURE RESEARCH 
 Future studies should incorporate more brands of exhalation filters to compare, as our 
study only utilized three commonly seen ones in the USA market. More nebulization tests for 
each exhalation filter should be conducted to simulate the clinical scenarios of more severe 
patients, who would need more frequent aerosol treatments per day (i.e. more than three). 
LIMITATION 
Our study has several limitations. Since it is an in-vitro study, the data gathered can not 
fully represent the ever-changing clinical context. For instance, the simulated lung model can 
not represent a real patient with different breathing patterns, tidal volume, lung characteristics, 
or anatomy. Nebulizers and exhalation filters used in our study can not represent all other 
varieties in the market. Finally, results from utilizing albuterol sulfate in our study can not 
represent all other drug formulations, as different drugs have distinct aerosol dynamics. 
CONCLUSION 
 The topic of occupational exposure to fugitive aerosol in healthcare environments has 
always been a concern. There are various methods to minimize fugitive aerosol, and placing a 
filter at the exhalation outlet of a nebulizer is one of them. According to our study results, there 
were no differences in the protection ability between the three tested filters within the first three 
nebulization tests and the average of them. Our findings also showed similar protection 
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efficiency between each test run for the same type of exhalation filter. In conclusion, it is safe 
to utilize any of the three tested exhalation filters during aerosol treatments as they provide 
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Supplemental Table 1  
Raw data for our study. Fugitive doses in mg are shown for each exhalation filter in the 
respective nebulization test and the average of 3 tests. 
Filter type Nebulizer 
number 
Fugitive dose 
on 1st test 
(mg) 
Fugitive dose 
on 2nd test 
(mg) 
Fugitive dose 
on 3rd test 
(mg) 
Mean fugitive dose (mg)  
 
Westmed 
1 .00548 .00750 .01223 .00840  
0.008400111 
 
2 .00934 .01453 .01084 .01157 
3 .00254 .00565 .00750 .00523 
 
Airlife 
1 .00363 .00409 .00565 .00446  
0.006612444 
 
2 .00375 .01246 .01251 .00957 
3 .00531 .00508 .00704 .00581 
 
Microgard 
1 .00611 .00657 .00421 .00563  
0.004568481 
 
2 .00323 .00248 .00294 .00288 
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Supplemental Figure 1 
Fugitive aerosol among three exhalation filters during each test run  
 
Fugitive aerosol escaping to the environment among the three exhalation filters for each test 
run are shown above (error bars show ±2 standard errors). 
 
